References
- 1. United States Pharmacopoeia 38 – National Formulary 33, USP Convention, Rockville (MD) 2015, p. 3869.
- 2. S. Klein, The use of biorelevant dissolution media to forecast the in vivo performance of a drug, AAPS. J.12 (2010) 397–406; DOI: 10.1208/s12248-010-9203-3.
- 3. Y. Qiu, Y. Chen, G. Zhang and W. Porter, Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice, Academic Press, London 2009, p. 411.
- 4. Sirius Analytical Instruments Ltd., New instrument for automated biorelevant biphasic dissolution and solubility testing, Eur. Pharmaceut. Rev. October 2013; http://www.americanpharmaceu-ticalreview.com/22313/news/featured-news-instrument-automated-biorelevant-biphasic-dissolution-solubility-testing/; last access date September 24, 2015.
- 5. A. Franc and J. Muselik, Method for Preparing Solid Drug from Warfarin Sodium Salt in Form of Isopropanol Clathrate, Involves Determining Total Weight of Solid Drug and Distribution Ratio of Warfarin Sodium Salt, Pat. CZ304136-B6, October 2013.
- 6. J. Muselik, A. Franc, P. Dolezel, R. Gonec, A. Krondlova and I. Lukasova, Influence of process parameters on content uniformity of a low dose active pharmaceutical ingredient in a tablet formulation according to GMP, Acta Pharm.64 (2014) 355–367; DOI: 10.2478/ACPH-2014-0022.
- 7. L. M. Vercaigne and G. G. Zhanel, Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on warfarins, J. Pharm. Pharm. Sci.1 (1998) 92–94.
- 8. V. R. S. Uppoor, Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations, J. Control. Release72 (2001) 127–132; DOI: 10.1016/S0168-3659(01)00268-1.